Norwich Pharmaceuticals (“Norwich”) is excited to announce a recent decision by its parent organization (Alvogen) to provide major capital investment in Plant and equipment. Starting immediately, there will be a projected investment of $26 million over the next two years, focused on increasing manufacturing capacity.
"This investment will allow us to acquire equipment upon which many of the newer drug products are being manufactured and sets us up to capture future business opportunities which otherwise would not have been possible. We are excited about what this represents for the future of the Norwich Pharmaceuticals and its ongoing contribution as a member of the local business community.” said Charlie Andrews, Vice President of Operations.
This represents the largest investment in the pharmaceutical manufacturing facility since its original construction in the 1970’s and will result in a larger footprint to the complex. In addition to manufacturing equipment, the investment will upgrade utilities and infrastructure, such as heating, cooling and purified water production. Engineering design is already underway and construction is scheduled to commence as soon as the ground thaws from this winter’s frost.